Target-specific Therapy With Pazopanib as Add-on to Vinflunine in Patients With Advanced or Metastatic Urothelial Carcinoma of the Bladder After Failure of Platinum-based Treatment.
Phase of Trial: Phase I/II
Latest Information Update: 07 Dec 2013
At a glance
- Drugs Pazopanib (Primary) ; Vinflunine (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Oct 2012 New source identified and integrated (German Clinical Trials Register, DRKS00004086).
- 01 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jan 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.